Alnylam Pharmaceuticals (ALNY) EBITDA Margin (2009 - 2026)
Alnylam Pharmaceuticals (ALNY) posted EBITDA Margin of 23.02% for Q1 2026, up 91.69% on a QoQ basis from 12.01% in Q4 2025, and up 1997.0% year-over-year from 1.1% in Q1 2025.
Alnylam Pharmaceuticals (ALNY) EBITDA Margin (2009 - 2026) Analysis & Trends
Alnylam Pharmaceuticals' EBITDA Margin history runs 18 years deep, the most recent figure standing at 23.02% for Q1 2026.
- Quarterly EBITDA Margin rose 1997.0% year-over-year to 23.02% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 17.54% (up 2246.0% YoY) and the FY2025 annual result came in at 13.51%, up 2137.0% from the prior year.
- EBITDA Margin was 23.02% for Q1 2026 at Alnylam Pharmaceuticals, up from 12.01% in the prior quarter.
- Across five years, EBITDA Margin topped out at 29.46% in Q3 2025 and bottomed at 97.63% in Q3 2022.
- A 5-year average of 23.18% and a median of 15.35% in 2024 frame the typical range for EBITDA Margin.
- Annual changes were most pronounced in 2023 — EBITDA Margin jumped 12612 bps — and 2024, when it plunged 4385 bps.
- Alnylam Pharmaceuticals' EBITDA Margin stood at 56.3% in 2022, then jumped by 53 bps to 26.47% in 2023, then jumped by 33 bps to 17.73% in 2024, then surged by 168 bps to 12.01% in 2025, then surged by 92 bps to 23.02% in 2026.
- Business Quant data shows ALNY's EBITDA Margin at 23.02% in Q1 2026, 12.01% in Q4 2025, and 29.46% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 16.51% |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 38.10% |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 17.83% |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 30.35% |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Alnylam Pharmaceuticals | 36.08 Bn | 33.07 Bn | 959.66 Mn | 23.02% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 23.02% |
| Dec 31, 2025 | 12.01% |
| Sep 30, 2025 | 29.46% |
| Jun 30, 2025 | -2.09% |
| Mar 31, 2025 | 3.04% |
| Dec 31, 2024 | -17.73% |
| Sep 30, 2024 | -15.35% |
| Jun 30, 2024 | 7.37% |
| Mar 31, 2024 | -8.79% |
| Dec 31, 2023 | -26.47% |
| Sep 30, 2023 | 28.50% |
| Jun 30, 2023 | -72.10% |
| Mar 31, 2023 | -46.92% |
| Dec 31, 2022 | -56.30% |
| Sep 30, 2022 | -97.63% |
| Jun 30, 2022 | -85.26% |
| Mar 31, 2022 | -68.80% |
| Dec 31, 2021 | -75.26% |
| Sep 30, 2021 | -96.83% |
| Jun 30, 2021 | -66.27% |